Levetiracetam Eignapharma

Levetiracetam, the active ingredient in Levetiracetam Eignapharma, is an anticonvulsant presented as an injectable solution for intravenous use. It is used to treat various seizure types in patients requiring rapid control. GNH USA supplies Levetiracetam Eignapharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levetiracetam is an anticonvulsant used in the management of seizure disorders.

Partial-onset seizures: reduces the frequency and severity of focal seizures. Myoclonic seizures: helps control sudden, brief muscle jerks. Generalized tonic-clonic seizures: decreases occurrence of full‑body convulsive episodes.

Levetiracetam may cause a range of adverse reactions, most of which are mild to moderate.

Common Side Effects: - Dizziness - Somnolence - Fatigue - Headache - Irritability - Nausea

Serious or Rare Side Effects: - Severe allergic reactions (anaphylaxis) - Stevens‑Johnson syndrome or other serious skin rashes - Suicidal thoughts or behavior - Blood dyscrasias (e.g., neutropenia) - Respiratory depression (rare) - Hepatic injury (rare)

Before initiating therapy, consider the following precautions.

Renal impairment: dose adjustment may be required based on renal function. Hepatic impairment: monitor liver function tests regularly. Concomitant CNS depressants: may increase sedation and respiratory depression. Pregnancy: safety not established; use only if benefit outweighs risk. Monitoring: periodic blood counts are advisable. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Levetiracetam can interact with several medications; assess the interaction potential before co‑administration.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels. - Phenytoin: may lower levetiracetam concentrations. - Rifampin: can decrease levetiracetam exposure.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): may enhance sedation. - Alcohol: can increase central nervous system effects. - Valproic acid: may raise levetiracetam levels, requiring monitoring.